Kidney News and Research

RSS

Racial disparities exist among living kidney donors, post donation: Research

Black and Hispanic kidney donors are significantly more likely than white donors to develop hypertension, diabetes and chronic kidney disease, according to new Saint Louis University research published in the August 19, 2010 issue of the New England Journal of Medicine.

20 Aug 2010

Quark Pharmaceuticals announces option agreement with Novartis for QPI-1002 siRNA drug

Silence Therapeutics plc, a leading international RNAi therapeutics company, is pleased to note that its partner, Quark Pharmaceuticals, Inc., has announced the grant of an option to Novartis to obtain an exclusive worldwide license to develop and commercialise QPI-1002, a p53 temporary inhibitor siRNA drug which incorporates Silence's AtuRNAi technology.

20 Aug 2010

Donor kidneys from deceased as good as those from brain-dead: Study

According to a new study from the UK, transplanted kidneys from patients whose hearts have stopped perform just as well as those from patients who are brain-dead but still alive. The former have been earlier considered to be weaker since the heart had stopped pumping blood into them before transplant. The study was published online by the The Lancet.

20 Aug 2010

Effects of illegal drugs on health

Illegal drugs are responsible for up to 1,600 deaths a year in the UK, and destroy thousands of relationships, families and careers. Find out about the most commonly used illegal drugs in England and Wales and the effects they can have on your health.

19 Aug 2010

70% rise in kidney disease in Australia over past 7 years: Report

According to a report released today by the Australian Institute of Health and Welfare (AIHW), with the rise of type II diabetes patients, there is increasing number of hospitalizations related to chronic kidney disease in Australia.

18 Aug 2010

Quark enters licensing option agreement with Novartis for p53 temporary inhibitor siRNA drug QPI-1002

Quark Pharmaceuticals, Inc., a world leader in the discovery and development of RNAi-based therapeutics, today announced that it has granted Novartis an option to obtain an exclusive worldwide license to develop and commercialize its p53 temporary inhibitor siRNA drug QPI-1002, currently the subject of a Phase II clinical trial.

18 Aug 2010

FDA grants orphan drug designation to NephRx's lead product NX001

NephRx Corporation today announced that the U.S. Food and Drug Administration has granted orphan drug designation to its lead product NX001 for the prevention of delayed graft function in renal transplant recipients. NX001 is a kidney growth factor peptide that has demonstrated good safety and promising efficacy in two animal models of acute renal failure.

18 Aug 2010

Genome-wide study identifies key genetic variant associated with nonalcoholic fatty liver disease

Researchers at Massachusetts General Hospital found that patients with nonalcoholic fatty liver disease (NAFLD) who carry an allele of the PNPLA3 gene have an increased risk of developing advanced disease, including nonalcoholic steatohepatitis (NASH), fibrosis, and cirrhosis. A second study supported by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) validates these findings and further concludes that in pediatric patients, the same allele is associated with earlier disease presentation.

18 Aug 2010

Research confirms genetic link to advanced fatty liver disease

17 Aug 2010

ImPACKD, The Kidney Foundation of Canada launch online resource for CKD patients

Before today, millions of Canadians living with chronic kidney disease did not have a strong online advocacy presence. Improving Patient Advocacy in Chronic Kidney Disease and The Kidney Foundation of Canada are now joining forces to provide an effective resource. Together, they are launching www.impackd.ca, a microsite of www.kidney.ca that is specifically designed for Canadians affected by chronic kidney disease.

17 Aug 2010

Sport Endurance develops new formula that enables safe consumption of Creatine

Sport Endurance, Inc, a health supplement company, has developed a revolutionary formula that enables the safe consumption of Creatine, a proven muscle-building and performance enhancing dietary supplement.

17 Aug 2010

BrickHouse Security, National Kidney Registry implement real-time GPS tracking system for organ shipment

BrickHouse Security, a leading provider of security and surveillance products to businesses and consumers, today announced that, in partnership with the National Kidney Registry (NKR), they have implemented the first real-time GPS tracking system for the shipment of living donor organs.

17 Aug 2010

FDA considers dropping Avastin approval, approves five-day emergency contraception pill

The Food and Drug Administration is considering revoking its approval of a last-ditch breast cancer drug over the debate on "medical spending and effectiveness that flared during the battle over health-care reform," The Washington Post reports. "The [FDA] is reviewing the recommendation of influential scientific advisers to revoke authorization of the drug to treat metastatic breast cancer.

17 Aug 2010

Researchers visualize ruptures of atherosclerotic plaques with multi-color CT and gold nanoparticles

Researchers from Mount Sinai School of Medicine have for the first time developed a way to visualize coronary artery plaques vulnerable to rupture using multi-color computed tomography (CT), an innovation that will lead to better and earlier diagnosis of cardiovascular disease. The data are published in the September issue of Radiology.

17 Aug 2010

Weikang Bio-Technology second-quarter revenue decreases 20.5% to $10.5 million

Weikang Bio-Technology Group Co., Inc., a leading developer, manufacturer and marketer of Traditional Chinese Medicine (TCM), Western prescription and OTC pharmaceuticals and other health and nutritional products in the People's Republic of China, today announced its fiscal 2010 second quarter results for period ended June 30, 2010.

16 Aug 2010

Belatacept study data to be presented at 23rd International Congress of The Transplantation Society

Bristol-Myers Squibb Company announced today that belatacept, an investigational selective T cell co-stimulation blocker being studied for use in solid organ transplantation, will be the subject of seven oral clinical presentations related to kidney transplantation at the 23rd International Congress of The Transplantation Society, being held August 15-19, 2010, in Vancouver, British Columbia, Canada. In total, 18 abstracts from company-sponsored studies will be presented during the congress.

16 Aug 2010

Treatment for diabetics cost U.S. hospitals 25% more than stays for non-diabetics

U.S. hospitals spent $83 billion in 2008 caring for people with diabetes, according to the latest News and Numbers from the Agency for Healthcare Research and Quality. In that year, nearly one of every five hospitalizations involved a person with diabetes.

16 Aug 2010

Kibow to support KDAE week for educating policymakers about kidney disease

Kibow Biotech would like to show its support for Kidney Disease Awareness and Education (KDAE) Week 2010, organized by American Nephrology Nurses' Association (ANNA). Kidney Disease Awareness and Education Week is a week dedicated to educating policymakers and their staff members about the needs of patients suffering from or at risk for end stage renal disease (ESRD).

13 Aug 2010

HIV infected injection drug users likely to have kidney disease: Study

Poor kidney function is common among injection drug users, particularly those with HIV, according to a study appearing in an upcoming issue of the Clinical Journal of the American Society Nephrology (CJASN). The results suggest that clinicians should monitor the kidney function of HIV-infected injection drug users and consider them candidates for medical treatments to protect their kidneys when appropriate.

13 Aug 2010

FDA grants LifeCycle Pharma SPA for LCP-Tacro pivotal Phase 3 study in 'de novo' kidney transplant patients

LifeCycle Pharma A/S today announced receipt of agreement with the U.S. Food and Drug Administration on a Special Protocol Assessment of its pivotal Phase 3 study, Study 3002, for LCP-Tacro in patients, who have just received a kidney transplant.

12 Aug 2010

Kidney News and Research

Racial disparities exist among living kidney donors, post donation: Research

Quark Pharmaceuticals announces option agreement with Novartis for QPI-1002 siRNA drug

Donor kidneys from deceased as good as those from brain-dead: Study

Effects of illegal drugs on health

70% rise in kidney disease in Australia over past 7 years: Report

Quark enters licensing option agreement with Novartis for p53 temporary inhibitor siRNA drug QPI-1002

FDA grants orphan drug designation to NephRx's lead product NX001

Genome-wide study identifies key genetic variant associated with nonalcoholic fatty liver disease

Research confirms genetic link to advanced fatty liver disease

ImPACKD, The Kidney Foundation of Canada launch online resource for CKD patients

Sport Endurance develops new formula that enables safe consumption of Creatine

BrickHouse Security, National Kidney Registry implement real-time GPS tracking system for organ shipment

FDA considers dropping Avastin approval, approves five-day emergency contraception pill

Researchers visualize ruptures of atherosclerotic plaques with multi-color CT and gold nanoparticles

Weikang Bio-Technology second-quarter revenue decreases 20.5% to $10.5 million

Belatacept study data to be presented at 23rd International Congress of The Transplantation Society

Treatment for diabetics cost U.S. hospitals 25% more than stays for non-diabetics

Kibow to support KDAE week for educating policymakers about kidney disease

HIV infected injection drug users likely to have kidney disease: Study

FDA grants LifeCycle Pharma SPA for LCP-Tacro pivotal Phase 3 study in 'de novo' kidney transplant patients

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Latest News